The Novel Drug Delivery Systems In Cancer Therapy Market Size is valued at USD 12.71 Billion in 2023 and is predicted to reach USD 63.25 Billion by the year 2031 at a 22.41 % CAGR during the forecast period for 2024-2031.
Key Industry Insights & Findings from the Report:
High-end drug delivery methods include expressing plant and bioactive extracts in microcapsules, liposomes, nano emulsions, nano capsules, hydrogels, microspheres, nanoparticles, and polymeric materials. Due to significant advantages over conventional medicines for cancer treatment, the market for novel drug delivery systems in cancer therapy is expected to grow. An increase in cancer occurrences significantly impacts the global market for novel drug delivery systems in cancer therapy. Additionally, there has been increased research activity to create novel drug delivery systems and increased financing for ongoing research initiatives.
The increase in the cost of healthcare for the detection and treatment of cancer is projected to contribute further to the expansion of the global market for novel drug delivery systems in cancer. Thus, with fresh investments and developments in the field, the high and rising burden of chronic diseases is anticipated to pave the way for developing novel drug delivery systems, and the studied market is thus expected to expand throughout the forecast period. Furthermore, the demand for novel drug delivery systems in cancer therapy is anticipated to increase due to technological developments in drug delivery systems, new investments made by private and public entities, new product launches, partnerships, and mergers and acquisitions by leading market players.
The novel drug delivery systems in the cancer therapy market are segmented based on product. Based on the product, the market is segmented into nanoparticles (liposomes, polymer, micelles, other nanoparticles) and embolization particles (PVA particles, drug-eluting beads, liquid emboli, and other embolization particles).
The nanoparticles segment is estimated to hold the largest share of the market. An innovative strategy for treating cancer uses nanoparticles as new drug delivery mechanisms. They enclose the medications and guard them against enzymatic and chemical deterioration. Long circulation half-lives, fewer adverse effects, and improved pharmacokinetics are all benefits of using nanoparticles in medication administration. Additionally, these particles have improved permeability, enabling effective medication delivery to cancer tissues.
North America region is projected to hold the largest share in the market of novel drug delivery systems in cancer therapy globally. The market is projected that the existence of various manufacturers and the availability of research funding will promote market expansion in North America or future developments in the global market for novel drug delivery systems in cancer therapy. The Asia Pacific regional market is expected to increase rapidly in the global novel drug delivery systems in cancer therapy due to the invention and introduction of technologically sophisticated drug delivery systems. Furthermore, the growing patient population with chronic diseases is predicted to propel market growth.
| Report Attribute | Specifications |
| Market Size Value In 2022 | USD 10.45 Billion |
| Revenue Forecast In 2031 | USD 62.44 Billion |
| Growth Rate CAGR | CAGR of 22.25 % from 2023 to 2031 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
| Historic Year | 2019 to 2022 |
| Forecast Year | 2023-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Product |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Teva Pharmaceutical Industries Ltd.; Johnson & Johnson Services, Inc.; GALEN; Merrimack Pharmaceuticals, Inc.; Shire; Samyang Biopharmaceuticals Corporation; Celgene Corporation; Spectrum Pharmaceuticals, Inc.; BTG. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
By Product
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Rest of Middle East and Africa
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.